Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.

Borissov, Borislav; Urbich, Michael; Georgieva, Boryana; Tsenov, Svetoslav; Villa, Guillermo

Borissov, Borislav; Urbich, Michael; Georgieva, Boryana; Tsenov, Svetoslav; Villa, Guillermo.

Afiliação

Borissov B; Prescriptia EOOD, Sofia, Bulgaria.
Urbich M; Amgen (Europe) GmbH, Economic Modeling Center of Excellence, Zug, Switzerland.
Georgieva B; Amgen Bulgaria EOOD, Value, Access & Policy, Sofia, Bulgaria.
Tsenov S; Amgen Bulgaria EOOD, Value, Access & Policy, Sofia, Bulgaria.
Villa G; Amgen (Europe) GmbH, Economic Modeling Center of Excellence, Zug, Switzerland.

J Mark Access Health Policy ; 5(1): 1412753, 2017.

Article em En | MEDLINE | ID: mdl-29321830

Palavras-chave

Bulgaria; Cardiovascular diseases; LDL; cholesterol; cost-effectiveness; evolocumab; hypercholesterolemia; lipoproteins; quality of care; statin; treatment outcome

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: J Mark Access Health Policy Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Bulgária País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google